Alzheimer disease therapeutics (Q34393812)

1 August 2017

1 reference

title

Alzheimer disease therapeutics (English)

1 reference

1 August 2017

0 references

Irizarry MC

1 reference

1 August 2017

Hyman BT

series ordinal

1 reference

1 August 2017

publication date

1 October 2001

1 reference

Journal of Neuropathology & Experimental Neurology

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

923-928

1 reference

Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Human memory and the cholinergic system. A relationship to aging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Morphological response of axotomized septal neurons to nerve growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Prospects for pharmacological intervention in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Mitochondrial involvement in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Regulation of amyloid precursor protein cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Tau in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

The basis for behavioural disturbances in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Assessment and management of behavioral disturbances in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNEN%2F60.10.923

21 January 2018

Identifiers

DOI

10.1093/JNEN/60.10.923

1 reference

1 August 2017

1 reference